# US 2013/0274226 A1 · Silica nanoparticle agent conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274226 A1
- Document ID: US20130274226A1
- Status: Published application
- Kind: A1
- Application number: 13/990,712
- Filed: 2011-11-30
- Published: 2013-10-17
- Earliest claimed: 2010-11-30
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Jianjun Cheng; Li Tang
- Web page: https://patentgrep.com/patent/US20130274226A1

## CPC

- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- A61P 35/00: Antineoplastic agents
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- B82B 1/008: {Nanostructures not provided for in groups B82B1/001 - B82B1/007}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82B: NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention provide a silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises, for example, an ester, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm. The invention also provides novel methods of making and using the silica nanoparticles described herein.

## Claims

### Claim 1

A silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises an ester, acetal, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The silica nanoparticle of claim 1 wherein the organic agent is a drug, a diagnostic agent, a surface modification agent, or a combination thereof.

### Claim 4 (depends on 1)

The silica nanoparticle of claim 1 wherein the silica nanoparticle degrades under physiological conditions.

### Claim 5 (depends on 4)

The silica nanoparticle of claim 4 wherein the organic agent is hydrolyzed from the linker L of the silica nanoparticle with controlled release kinetics under physiological conditions.

### Claim 6 (depends on 5)

The silica nanoparticle of claim 5 wherein the linker L is responsively degradable.

### Claim 7 (depends on 6)

The silica nanoparticle of claim 6 wherein the surface of the nanoparticle comprises surface-modifying groups.

### Claim 8 (depends on 7)

The silica nanoparticle of claim 7 wherein the surface-modifying group comprises PEG groups.

### Claim 9 (depends on 3)

The silica nanoparticle of claim 3 wherein the drug is paclitaxel, camptothecin, docetaxel or doxorubicin.

### Claim 10 (depends on 3)

The silica nanoparticle of claim 3 wherein the diagnostic agent is an optical imaging agent, a magnetic resonance imaging agent, or a positron emission tomography agent.

### Claim 11 (depends on 3)

The silica nanoparticle of claim 3 wherein the diagnostic agent is pyrene, rhodamine B, IR783, Gd-EDTA, or 64Cu-EDTA.

### Claim 12 (depends on 6)

The silica nanoparticle of claim 6 wherein the linker L comprises one or more of:
wherein n is 0-8 and X1 is CH2 or S;
wherein n is 0-8 and X is O or S; or
c) —(C1-C8)alkyl-S—.

### Claim 13 (depends on 12)

The silica nanoparticle of claim 12 wherein the silica nanoparticle matrix comprises one or more Si-ester-Si groups, Si-acetal-Si groups, or both;
wherein the Si-ester-Si group comprises a moiety of Formula I:
wherein each m is independently 1-8 and each X3 is a silicon atom of the silica nanoparticle matrix; and
wherein the Si-acetal-Si group comprises a moiety of Formula II:
wherein each p is independently 1-8 and each X3 is a silicon atom of the silica nanoparticle matrix.

### Claim 14 (depends on 13)

The silica nanoparticle of claim 13 wherein the silica nanoparticle matrix comprises one or more Si-ester-Si groups, Si-acetal-Si groups, or both;
wherein the Si-ester-Si group comprises a moiety of Formula IA:
wherein each X3 is an oxygen atom of the silica nanoparticle matrix; and
wherein the Si-acetal-Si group comprises a moiety of Formula IIA:
wherein each X3 is an oxygen atom of the silica nanoparticle matrix.

### Claim 15 (depends on 14)

The silica nanoparticle of claim 14 wherein the diameter of the particle is about 15 nm to about 200 nm.

### Claim 16 (depends on 14)

The silica nanoparticle of claim 14 wherein the diameter of the particle is about 15 nm to about 50 nm.

### Claim at position 17

-23. (canceled)

### Claim 24

A method of preparing organic agent conjugated silica nanoparticles comprising:
a) combining tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS) and optionally one or more Si-ester-Si compounds, Si-acetal-Si compounds, or both;
wherein the Si-ester-Si compound comprises a moiety of Formula IB:
wherein each m is independently 1-8 and each R is independently (C1-C4)alkyl; and
wherein the Si-acetal-Si compound comprises a moiety of Formula IIB:
wherein each p is independently 1-8 and each R is independently (C1-C4)alkyl;
with methanol or ethanol; water, and ammonium hydroxide, to provide a first mixture;
b) adding a plurality of organic agents to the first mixture, wherein each organic agent is conjugated to a trialkoxysilane group, to provide a second mixture; and
c) stirring or agitating the second mixture;
to provide the organic agent conjugated silica nanoparticles, wherein the silica nanoparticles comprise non-porous matrixes of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises an ester, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm.

### Claim 25 (depends on 24)

The method of claim 24 wherein the surfaces of the silica nanoparticles are modified by combining the second mixture with PEG conjugated trialkoxysilanes, to provide silica nanoparticles with PEG moieties conjugated to the surface of the nanoparticles.

### Claim 26

(canceled)

### Claim 27

A method of preparing organic agent conjugated silica nanoparticles comprising:
a) combining cyclohexane, hexanol, and a non-ionic surfactant comprising a phenyl moiety substituted by a (C6-C10)alkyl group and a PEG group having 6-12 ethylene oxide units, to provide a first mixture;
b) combining the first mixture with water, tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS), optionally one or more Si-ester-Si compounds, Si-acetal-Si compounds, or both;
wherein the Si-ester-Si compound comprises a moiety of Formula IB:
wherein each m is independently 1-8 and each R is independently (C1-C4)alkyl; and
wherein the Si-acetal-Si compound comprises a moiety of Formula IIB:
wherein each p is independently 1-8 and each R is independently (C1-C4)alkyl, and a plurality of organic agents, wherein each organic agent is conjugated to a trialkoxysilane group, to provide a second mixture; and
c) combining the second mixture with ammonium hydroxide with stifling or agitation, to provide the organic agent conjugated silica nanoparticles, wherein the silica nanoparticles comprise non-porous matrixes of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises an ester, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm.

### Claim 28 (depends on 27)

The method of claim 27 wherein the surfaces of the silica nanoparticles are modified by combining organic agent conjugated silica nanoparticles with PEG conjugated trialkoxysilanes, to provide silica nanoparticles with PEG moieties conjugated to the surface of the nanoparticles.

### Claim 29

(canceled)

### Claim 30 (depends on 15)

A method of enhancing the penetration of a drug into a tumor comprising administering an effective amount of a plurality of silica nanoparticles of claim 15 to a mammal that has a tumor, wherein the particles enter the tumor, and the nanoparticles release the drug to the tumor.

### Claim 31

(canceled)

### Claim 32 (depends on 3)

A pharmaceutical composition comprising a plurality of silica nanoparticles of claim 3 and a pharmaceutically acceptable diluent, excipient, or carrier.

### Claim 33 (depends on 3)

A method for delivering a therapeutic agent to an animal in need of treatment with the agent comprising administering a plurality of silica nanoparticles of claim 3 to the animal, wherein the therapeutic agent releases from the linker L under the physiological conditions of the animal, thereby delivering the therapeutic agent to the animal.

### Claim 34 (depends on 1)

A composition comprising a plurality of silica nanoparticles of claim 1 and a lyoprotectant.

### Claim 35 (depends on 34)

The composition of claim 34 wherein the lyoprotectant comprises dextrose.
